Introduction of p21(Waf1/Cip1) gene into a carcinoma cell line of the uterine cervix with inactivated p53

Cancer Letters

Volumn 116, Issue 2, 1997, Pages 233-239

  Yokoyama, Yasuhiro ^a   Takahashi, Yuichiro ^a   Morishita, Shigeo ^a   Hashimoto, Midori ^a   Tamaya, Teruhiko ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carcinoma of the cervix; Cyclin dependent kinase; p21; Papilloma viruses; Telomerase

Indexed keywords

CYCLIN DEPENDENT KINASE; DEXAMETHASONE; PROTEIN P21; PROTEIN P53; TELOMERASE;

ARTICLE; CARCINOMA CELL; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DNA TRANSFECTION; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GENE INDUCTION; GENE TRANSFER; GROWTH RETARDATION; HELA CELL; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA; WART VIRUS;

CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; FLOW CYTOMETRY; GENES, P53; HELA CELLS; HUMANS; TELOMERASE; TRANSFECTION; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS;

EID: 0030832263     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(97)00193-6     Document Type: Article

References (28)

1. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
2. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-704.
3. Noda A., Ning Y., Venable S.F., Pereira-Smith O.M., Smith J.R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression system. Exp. Cell Res. 211:1994;90-98.
4. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
5. Cip1 in muscle and other terminally differentiating cells. Science. 267:1995;1024-1027.
6. WAF1. Cancer Res. 55:1995;4536-4539.
7. Yang Z.Y., Perkins N.D., Ohno T., Nabel E.G., Nabel G.J. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat. Med. 1:1995;1052-1056.
8. Steinman R.A., Hoffman B., Iro A., Guilouf C., Liebermann D.A., El-Houseini M.E. Induction of p21 (WAF1/CIP1) during differentiation. Oncogene. 9:1994;3389-3396.
9. Jiang H., Lin J., Su Z.Z., Herlyn M., Kerbel R.S., Weissman B.E., Welch D.R., Fisher P.B. The melanoma differentiated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation, and progression in human melanoma cells. Oncogene. 10:1995;1855-1864.
10. Zhang W., Grasso L., McClain C.D., Gambel A.M., Cha Y., Travali S., Deisseroth A.B., Mercer W.E. P53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res. 55:1995;668-674.
11. Howley P.M. Role of the human papilloma viruses in human cancer. Cancer Res. 51:1991;5019S-5022S.
12. Werness B.A., Levine A.J., Howley P.M. Association of human papilloma viruses types 16 and 18 E6 proteins with p53. Science. 248:1990;76-79.
13. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papilloma virus types 16 and 18 promote the degradation of p53. Cell. 63:1990;1129-1136.
14. Harris C.C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88:1996;1442-1455.
15. Zimmerman K., Weber S., Dobrovnik M., Hauber J., Bohnlein E. Expression of chimeric neo-Rev response element sequences interferes with Rev-dependent HIV-1 Gag expression. Hum. Gene Ther. 3:1992;155-161.
16. Kim N.M., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L.C., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:1994;2011-2015.
17. Wright W.E., Shay J.W., Piatyszek M.A. Modification of a telometric repeat amplification protocol (TRAP) results in increased reliability, linearity and sensitivity. Nucleic Acid Res. 23:1995;3794-3795.
18. Liang X.H., Mungal S., Ayscue A., Meissner J.D., Wodnicki P., Hockenbery D., Lockett S., Herman B. Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. J. Cell. Biochem. 57:1995;509-521.
19. Chen J., Jackson P.K., Kirschner M.W., Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature. 374:1995;386-388.
20. Luo Y., Hurwitz J., Massague J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21. Nature. 375:1995;159-161.
21. Waga S., Hannon G.J., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 369:1994;574-578.
22. Harper J.W., Elledge S.J., Keyomarsi K., Dynlacht B., Tsai L.H. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell. 6:1995;387-400.
23. Allsopp R.C., Chang E., Kashefi-Aazam M., Rogaev E.I., Piatyszek M.A., Shay J.W., Harley C.B. Telomere shortening is associated with cell division in vitro and in vivo. Exp. Cell Res. 220:1995;194-200.
24. Harley C.B., Villeponteau B. Telomeres and telomerase in aging and cancer. Curr. Opin. Genet. Dev. 5:1995;249-255.
25. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 55:1995;2910-2919.
26. Sharma H.W., Sokoloski J.A., Perez J.R., Maltese J.Y., Sartorelli A.C., Stein C.A., Nichols G., Khaled Z., Telang N.T., Narayanan R. Differentiation of immortal cells inhibits telomerase activity. Proc. Natl. Acad. Sci. USA. 92:1995;12343-12346.
27. Zhu X., Kumar R., Mandal M., Sharma N., Sharma H.W., Dhingra U., Sokoloski J.A., Hsiaom R., Narayanan R. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc. Natl. Acad. Sci. USA. 93:1996;6091-6095.
28. Holt S.E., Wright W.E., Shay J.W. Regulation of telomerase activity in immortal cell lines. Mol. Cell. Biol. 16:1996;2932-2939.